TD Cowen analyst Jason Gabelman lowered the firm’s price target on Calumet Specialty Products (CLMT) to $26 from $27 and keeps a Buy rating on the shares. The firm said the company reiterated confidence in receiving DOE loan funds and guidance on use of funds and it does not see a need for equity issuance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Reports Q3 2024 Earnings Amid Strategic Shifts
- Calumet Specialty Products reports Q3 EPS ($1.18), consensus (74c)
- CLMT Upcoming Earnings Report: What to Expect?
- Calumet Specialty Products reports preliminary Q3 adjusted EBITDA $45M-$55M
- Calumet Specialty Products price target raised to $29 from $25 at Wells Fargo